![]() |
HIV-Related Drug Classes Navigation |
||
| Anti-HIV Drug Classes (Home) | ||
|
||||||||
Enfuvirtide (Fuzeon ®)
|
||||||||
|
Fusion protein inhibitor. Dosing (Adults): 90 mg SQ twice daily. (Administer subcutaneously into upper arm, abdomen, or anterior thigh.) Supplied: Injection (powder for reconstitution): 108 mg (90 mg/ml following reconstitution). |
||||||||
maraviroc (Selzentry™)
|
||||||||
|
Mechanism of Action Maraviroc is a member of a therapeutic class called CCR5 co-receptor antagonists. Maraviroc selectively binds to the human chemokine receptor CCR5 present on the cell membrane, preventing the interaction of HIV-1 gp120 and CCR5 necessary for CCR5-tropic HIV-1 to enter cells. CXCR4-tropic and dual-tropic HIV-1 entry is not inhibited by maraviroc INDICATIONS AND USAGE SELZENTRY, in combination with other antiretroviral agents, is indicated for treatment-experienced adult patients infected with only CCR5-tropic HIV-1, who have evidence of viral replication and HIV-1 strains resistant to multiple antiretroviral agents. This indication is based on analyses of plasma HIV-1 RNA levels in two controlled studies of SELZENTRY of 48 weeks duration. Both studies were conducted in clinically advanced, 3-class antiretroviral (NRTI, NNRTI, PI, or enfuvirtide) treatment-experienced adults with evidence of HIV-1 replication despite ongoing antiretroviral therapy. The following points should be considered when initiating therapy with SELZENTRY: Tropism testing is required for the appropriate use of SELZENTRY. Use of SELZENTRY is not recommended in patients with dual/mixed or CXCR4-tropic HIV-1 as efficacy was not demonstrated in a phase 2 study of this patient group. The safety and efficacy of SELZENTRY have not been established in treatment-naïve adult patients or pediatric patients. Recommended Dosing Regimen
Supplied: Tablets: 150 mg and 300 mg |
||||||||
raltegravir (Isentress ®)
|
||||||||
|
INDICATIONS AND USAGE: ISENTRESS™ is a human immunodeficiency virus integrase strand transfer inhibitor (HIV-1 INSTI) indicated: • In combination with other antiretroviral agents for the treatment of HIV-1 infection in treatment-experienced adult patients who have evidence of viral replication and HIV-1 strains resistant to multiple antiretroviral agents . The safety and efficacy of ISENTRESS have not been established in treatment-naïve adult patients or pediatric patients Dosing (Adults): 400 mg administered orally, twice daily with or without food Supplied: Tablets: 400 mg |
||||||||
Disclaimer
|
||||||||
|
Listed dosages are for - Adult patients ONLY. PLEASE READ THE
DISCLAIMER CAREFULLY BEFORE
ACCESSING OR USING THIS SITE. BY ACCESSING OR USING THIS SITE, YOU AGREE
TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER.
GlobalRPH does not directly or indirectly practice medicine or provide
medical services and therefore assumes no liability whatsoever of any
kind for the information and data accessed through the Service or for
any diagnosis or treatment made in reliance thereon. David F. McAuley, Pharm.D., R.Ph. GlobalRPh Inc. |
| Disclaimer Contact Us Privacy Policy Website Search | We comply with the HONcode standard for health trustworthy information: Verify here. Copyright © 2007 GlobalRPh Inc. |
![]() |
|
